WEdnesday, june 17 10:00AM ET
De-Risked Base Business, Broad Utility Platform Technologies, and Innovative Business Model
Gilles Gagnon, M.Sc., MBA
President and Chief Executive Officer
Gilles Gagnon serves as the President and Chief Executive Officer of Ceapro. Prior to joining Ceapro, he was President and CEO of Aeterna Zentaris, a Nasdaq-listed biopharmaceutical company. During the past 35 years, Mr. Gagnon has worked at several management levels within the field of health, especially in the hospital environment and pharmaceutical industry. Before going to Aeterna Zentaris in 1999, Mr. Gagnon was Vice President, external affairs for Novartis Pharma Canada Inc. from 1996 to 1999. Prior to that, from 1989 to 1996, Mr. Gagnon held various positions including Executive Director, Corporate Planning and Business Development, Senior Director, Strategic Alliances, General Manager, Government Affairs and Access to Market and Director of Professional Services at Sandoz Pharmaceuticals Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development and commercialization of "active ingredients" derived from oats and other renewable plant resources for healthcare and cosmetic industries. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.
Ceapro's patented process technologies include Pressurized Gas eXpanded (PGX) technology which is a unique and disruptive technology with several key advantages over conventional drying and purification methods that can be used to generate novel high-value biopolymers and biocomposites structures with micro or nano-sized features. Ceapro also utilizes its proprietary plant extraction-based manufacturing process to supply ingredients to well-known personal care and cosmetic industries worldwide.
Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor All rights reserved.
